title: Paired tumor marker of soluble E-selectin and its ligand sialyl Lewis A in colorectal cancer.
abstract: BACKGROUND
  Better diagnosis of metastatic disease has been pursued by oncologists: however, many of the tumor markers have been still controversial. Our purpose was to estimate the usefulness of soluble E-selectin and its ligand sialyl Lewis A for more accurate diagnosis as a combined tumor marker for metastases in colorectal cancer.
  
  
  METHODS
  E-selectin and sialyl Lewis A, collected from preoperative blood, were measured of its levels in 54 patients with colorectal cancer classified according to Dukes' stage. E-selectin was assayed by enzyme-linked immunosorbent assay, whereas sialyl Lewis A was quantified by enzyme immunoassay using immunoclone kit.
  
  
  RESULTS
  The elevation in the level of E-selectin was significantly higher in Dukes' D group than that of healthy volunteers (P < 0.001, Fisher's procedure of least significance test), Dukes' A (P = 0.01), B (P = 0.025) and C (P < 0.01). Significantly higher level of sialyl Lewis A was shown in the group of metastases than that of non-metastases (P < 0.0068. Student's t-test). Paired elevation of E-selectin and sialyl Lewis A was significantly higher in the hematogenous metastases than non-metastases (P < 0.001, Fisher exact test).
  
  
  CONCLUSIONS
  These results suggest that E-selectin could play some role in the progress of hematogenous metastases. The elevation of E-selectin alone or both E-selectin and sialyl Lewis A may be one of the useful indexes for more precise diagnosis of hematogenous metastases of human colorectal cancer.
authors.affiliation: Second Department of Surgery, School of Medicine, Nagoya University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ito
authors.forename: C L
authors.initials: CL
authors.lastname: Ye
authors.forename: K
authors.initials: K
authors.lastname: Hibi
authors.forename: C
authors.initials: C
authors.lastname: Mitsuoka
authors.forename: R
authors.initials: R
authors.lastname: Kannagi
authors.forename: K
authors.initials: K
authors.lastname: Hidemura
authors.forename: H
authors.initials: H
authors.lastname: Ando
authors.forename: Y
authors.initials: Y
authors.lastname: Kasai
authors.forename: S
authors.initials: S
authors.lastname: Akiyama
authors.forename: A
authors.initials: A
authors.lastname: Nakao
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen; D002277:Carcinoma / Q000097:blood* / Q000175:diagnosis* / Q000556:secondary; D015179:Colorectal Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000473:pathology; D019040:E-Selectin / Q000097:blood*; D005260:Female; D006801:Humans; D008024:Ligands; D008113:Liver Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000556:secondary; D008207:Lymphatic Metastasis / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009844:Oligosaccharides / Q000097:blood*; D010534:Peritoneal Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000556:secondary
chemical_list: D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D019040:E-Selectin; D008024:Ligands; D009844:Oligosaccharides